Auglurant is primarily explored for its potential therapeutic applications in the field of neurology and psychiatry. It is investigated as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5), which plays a significant role in the central nervous system. By modulating this receptor, it may help in managing conditions such as anxiety, depression, and fragile X syndrome. Research suggests that targeting mGluR5 could offer a novel approach to treating these disorders, potentially providing benefits where traditional therapies have limitations. Its application is still under study, with ongoing clinical trials to determine efficacy and safety in humans.